HIND

Business Context and Reporting Period

Company: ReShape Lifesciences Inc. (Note: Request metadata listed "Vyome Holdings," but the filing is for ReShape Lifesciences, which is entering a merger with Vyome Therapeutics).

Reporting Period: Quarterly period ended June 30, 2024 (Form 10-Q).

Business Overview: ReShape is a global weight-loss solutions company offering the Lap-Band Adjustable Gastric Banding System. The company is currently in a development phase for the Diabetes Bloc-Stim Neuromodulation device and has no revenue from the Obalon Balloon System. On July 8, 2024, ReShape entered into a Merger Agreement with Vyome Therapeutics, Inc. and an Asset Purchase Agreement to sell substantially all assets to Ninjour Health International Limited (an affiliate of Biorad).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 12.8% year-over-year for the quarter and 13.9% for the six-month period. Management attributes this primarily to decreased sales volume due to competition from GLP-1 pharmaceutical weight-loss alternatives.
• Expense Reduction: Operating expenses decreased significantly. Sales and marketing expenses dropped 69.2% (quarter) and 61.3% (six months) due to a shift to targeted digital marketing and reduced payroll. General and administrative expenses fell 13.3% (quarter) and 40.1% (six months) due to reduced staffing and professional service fees.
• Gain on Extinguishment of Debt: The company recognized a $0.429 million gain in both the quarter and six-month periods. This resulted from writing off accounts payable totaling $429,000 that were deemed time-barred under the statute of limitations.
• Warrant Liability: The company recorded a gain of $18,000 on changes in the fair value of liability warrants for the six months ended June 30, 2024, compared to a gain of $3.438 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing raises substantial doubt about the company's ability to continue as a going concern. Management states that without the completion of the planned merger and asset sale, or additional financing, the company expects to run out of cash during the third quarter of 2024.
• Strategic Transactions:
  • Merger: ReShape plans to merge with Vyome Therapeutics, Inc.
  • Asset Sale: ReShape plans to sell substantially all assets to Ninjour Health (Biorad affiliate) for approximately $5.16 million in cash.
  • Financing: Concurrent financing agreements are in place for up to $7.3 million in securities.
• Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting due to insufficient internal resources with appropriate accounting expertise. This led to errors in inventory review, accounts payable, and functional currency application.
• Legal Proceedings: A prior judgment against the company by Cowen and Company, LLC for $1.35 million plus fees was paid in full as of June 30, 2024.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to fund operations through Q3 2024 pending the closing of the merger and asset sale.
• Transaction Closing: Monitor the status of the Merger Agreement with Vyome and the Asset Purchase Agreement with Ninjour Health, as these are critical to the company's survival.
• Revenue Trends: Assess the long-term impact of GLP-1 pharmaceuticals on the Lap-Band product line revenue.
• Internal Controls: Review the remediation plan for the identified material weakness in financial reporting controls.
• Debt Write-off: Confirm the accounting treatment and legal basis for the $429,000 gain on extinguishment of debt.